HUMIRA 40 MG INJ SRG 0,8 ML + T
(Adalimumab) - Maladie rare sans désignation orpheline
*In combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 2 to 17 years who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs).
*As monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate
Humira has not been studied in children aged less than 2 years.
*Treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy.